Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of metformin as a repurposed
agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to
standard neo-adjuvant chemotherapy.